Riskpilot← Back to searchSign inGet full accessCOCHLEAR NORWAY AS
ASActiveOrg 999642993Brynsveien 13, 0667 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20138 employeeswww.cochlear.no
Revenue 2025
NOK 42,1M
-1% vs 2024
EBITDA margin
4.5%
+1% vs 2024
Equity ratio
45.6%
Financial strength
Net profit 2025
NOK 1,5M
-2% vs 2024
| Revenue | NOK 42,1M | -1% |
| EBITDA | NOK 1,9M | +1% |
| Net profit | NOK 1,5M | -2% |
| Total assets | NOK 15,7M | +6% |
| Equity | NOK 7,2M | +27% |
| Employees | 8 | — |
Legal name
COCHLEAR NORWAY AS
Org number
999642993
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4. februar 2013
Share capital
NOK 510 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Virksomhet innen implanterbare hørselsløsninger.
Address
Brynsveien 13, 0667 Oslo
Website
www.cochlear.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 30 414 | 32 836 | 46 856 | 42 620 | 42 118 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 1 058 | 1 509 | 2 147 | 1 863 | 1 887 |
| Depreciation & amort. | −68 | −47 | −2 | −0 | −1 |
| EBIT | 990 | 1 462 | 2 145 | 1 863 | 1 886 |
| Net financials | 6 | 31 | 26 | 129 | 89 |
| Profit before tax | 996 | 1 492 | 2 171 | 1 993 | 1 975 |
| Tax | 328 | −0 | −0 | −0 | −0 |
| Net profit | 668 | 1 164 | 1 693 | 1 554 | 1 522 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 19 926 | 18 274 | 18 362 | 14 881 | 15 749 |
| Equity | 4 754 | 5 918 | 7 611 | 5 666 | 7 187 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 15 172 | 12 355 | 10 750 | 9 215 | 8 562 |
| Total debt | 15 172 | 12 355 | 10 750 | 9 215 | 8 562 |
EBITDA margin
4.5%
This company
15.8%
Market median
-72% vs market
20212025
Equity ratio
45.6%
This company
38.2%
Market median
+19% vs market
20212025
Return on equity
21.2%
This company
18.4%
Market median
+15% vs market
20212025
Net profit margin
3.6%
This company
8.1%
Market median
-56% vs market
20212025
Asset turnover
2.67×
This company
1.12×
Market median
+138% vs market
20212025
Debt / equity
1.19×
This company
0.62×
Market median
-92% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JA Chief Executive Officer | Chief Executive Officer | 2013 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Former (2) | ||
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2017 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Cochlear Europe Ltd | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of COCHLEAR NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jørgen Alexander Sætre | Chief Executive Officer | 0 companies |
| Peter Bart J Van Gerwen | Chairman | 0 companies |
| Anna Maria Therese Helling | Board of Directors | 0 companies |
| Sarah Elizabeth Thom | Board of Directors | 0 companies |
| Stuart Ross Sayers | Board of Directors | 0 companies |
| David Thomas Mark Ashton | Board of Directors | 0 companies |